The Patent Finder
AB

Akeso Biopharma, Inc.

First filing 2017
OverviewNotableFeesChangesFamiliesPatent listSources & methods

17 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jul 2035. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jul 2035
Next term end
15
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 30, 2026
    The maintenance fee for ANTI-VEGF-PD1 Bispecific Antibody with Novel Structure and Use Thereof (US 11,661,454) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
  • 1 fee due Apr 22, 2027
    The maintenance fee for An ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses (US 10,449,251) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

What they patent

The 5 largest of its 15 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 11,291,720ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses
In force
 · High confidence
In forceHigh confidence
US 12,447,208ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses
In force
 · High confidence
In forceHigh confidence
US 10,449,251An ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses
In force
 · High confidence
In forceHigh confidence
US 11,104,734ANTI-PD-1 Monoclonal Antibody
In force
 · High confidence
In forceHigh confidence
US 10,858,433Monoclonal Antibody Against PD-1 and Application Thereof
In force
 · High confidence
In forceHigh confidence
US 12,076,398ANTI-PD1 Monoclonal Antibody, Pharmaceutical Composition Thereof and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 11,479,608ANTI-CTLA4 Antibodies
In force
 · High confidence
In forceHigh confidence
US 12,195,527ANTI-PD-1/VEGFA Bifunctional Antibody, Pharmaceutical Composition Thereof
In force
 · Medium confidence
In forceMedium confidence
US 11,680,095Monoclonal Antibody Against Nerve Growth Factor, and Encoding Gene and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 11,661,454ANTI-VEGF-PD1 Bispecific Antibody with Novel Structure and Use Thereof
In force
 · High confidence
In forceHigh confidence
10 of 17 patents shown.
Pro members see all 17.
Pro members: see all 17 patents
Also on record, not counted in the 17: 28 applications pending · 1 application abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited